DOCSLIB.ORG

1-DAY ACUVUE, Contact Lenses ACIPHEX/PARIET

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1-DAY ACUVUE, Contact Lenses ACIPHEX/PARIET 1-DAY ACUVUE, contact lenses ACIPHEX/PARIET (rabeprazole sodium), for gastrointestinal conditions (non-J&J trademark) ACT, rinse ACTIVE NATURALS, ingredients derived from nature ACUVUE, contact lenses ACUVUE 2 COLOURS, contact lenses ACUVUE ADVANCE, contact lenses ACUVUE OASYS, contact lenses ADVANCED SOLUTIONS, cosmetic dermatology products ALAMAST, penmirotast potassium ophthalmic solution (non-J&J trademark) AMBI, skin care for women of color ANTIVIROGRAM, HIV drug resistance testing ARESTIN (rninoeycline HCl 1 mg), for periodontal. disease AVEENO, skin care products AXERT, (almotriptan malate tablets) for acute migraine treatment BABYCENTER, resources for new and expectant parents BAND-AID, adhesive bandages BENECOL, food spread (non-J&J trademark) BETIMOL, timolol ophthalmic solution (non-J&J trademark) BIAFINE, skin healing brand on the French market BX VELOCITY, stent CAREFREE, Pantiliners CARTO, cardiac navigation system CARTOMERGE, image integration software module CELLSEARCH, assays for circulating tumor cells CELSIUS, diagnostic ablation steerable tip catheter CHARITE, artificial spinal disc CIDEX, instrument sterilization, disinfection, and cleaning technologies CLEAN & CLEAR, teen skin care products COMFORT-FLEX, adhesive CONCERTA (methylphenidate HC1), treatment of attention deficit hyperactivity disorder CONCORDE, implant and instrument system for spinal surgery CONTOUR, curved cutter stapler CYPHER, Sirolimus-eluting Stent DEPUY ASR, bearings for joint stability DEPUY PROXIMA, hip implant DERMABOND, topical skin adhesive DITROPAN XL (oxybutynin chloride), treatment of overactive bladder DOXIL (doxorubicin HC1 liposome injection), treatment of relapsed and refractory ovarian cancer. D-TRANS, transdermal system DRYTECH SYSTEM, sanitary protection system DURAGESIC (fentanyl transdermal system, sold abroad as DUROGESIC), for chronic pain ECHELON 60 ENDOPATH, stapler for laparoscopic surgery ELMIRON (pentosan polysulfate sodium), for women’s health ENDOPATH XCEL, trocar for laparoscopic surgery EPREX/ERYPO (Epoetin alfa), hematology and nephrology ESSENTIAL MOISTURE, Aveeno lip conditioner ETHICON OMNEX, surgical sealant E-TRANS, drug delivery system EXPEDIUM, spine system FEVERFEW PFE, skin care for sensitive skin FLEXERIL, FRONTRUNNER, catheter GENESEARCH, assays to characterize tumors GYNECARE PROLIFT, pelvic floor repair systems HARMONIC, ultrasonic cutting and coagulating surgical devices HARMONIC ACE, curved shear surgical device HYDRACLEAR, contact lens material ID-MICRO TYPING SYSTEM (ID-MTS), line of reagents and supplies IMODIUM, anti-diarrheal INDEPENDENCE iBOT, mobility system IONSYS, (fentanyl hydrochloride (HCl) patient-activated transdermal system ISOCOOL, bipolar forceps JOHNSON'S, baby line of products K-Y, personal lubricant LACTAID, milk and dietary supplements LCS, total knee system LEUSTATIN (cladribine), hairy cell leukemia treatment LEVAQUIN (levoloxacin), anti-infective and a leading quinolone antibiotic (non- J&J trademark) MAMMOTOME, breast biopsy system MICROHIP, instruments and educational services for a minimally invasive surgical technique MONISTAT, vaginal yeast cure MOTRIN, ibuprofen products MULTIPASS, needles MYLANTA, antacid NATRECOR (nesiritide), for congestive heart failure NEUTROGENA VISIBLY CLEAR, line of cleansing and acne products NIZORAL A-D Shampoo. NORATAK, treatment for acutely decompensated heart failure (non-J&J trademark) o.b., tampons ONETOUCH, blood glucose monitoring products ONETOUCH HORIZON, blood glucose monitoring system ONETOUCH ULTRA, blood glucose monitoring system OROS, oral drug delivery ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system), contraceptive patch ORTHO TRI-CYCLEN, (norgestimate/ethinyl estradiol), contraceptive ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol), a low dose oral contraceptive ORTHOCLONE OKT 3, monoclonal antibody used to treat organ transplant rejection ORTHOCORD, orthopaedic suture for knee and shoulder repair OUTBACK LTD., Re-Entry Catheter devices PALMAZ, stent PIPELINE, access system for spinal surgery PEPCID, acid controller (non-J&J trademark) PIZ BUIN, sun tan products PREVACARE, antimicrobial hand gel PROCEED, tissue separating mesh PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology derived product that stimulates red blood cell production PROPULSID (cisapride) QUICKANCHOR, suture QUIXIN (levofloxacin), ophthalmic solution (non-J&J trademark) RAZADYNE, (galantamine hydrobromide), for symptoms of mild to moderate Alzheimer’s disease REACH, toothbrushes REMBRANDT, tooth whitening products REMICADE (infliximab), therapy indicated to treat the symptoms of Crohn's disease, rheumatoid arthritis and ankylosing spondylitis REMINYL (galantamine HBr), for patients with mild to moderate Alzheimer's disease RhoGAM, an injectable drug used to prevent hemolytic disease of the newborn RISPERDAL (risperidone) and RISPERDAL CONSTA (risperidone long-acting injection), for treatment of the symptoms of schizophrenia RoC, skin care products SOFTLOTION, baby and kids lotion SOFTWASH, baby and kids wash SOOTHING NATURALS, baby skin care products SPLENDA, no calorie sweetener SPORANOX (itraconazole), for fungal infections ST. JOSEPH, adult regimen aspirin STAYFREE, sanitary protection products STEALTH, drug delivery technology STERRAD, instrument sterilization, disinfection, and cleaning technologies TIBOZOLE (miconazole nitrate 10 mg), HIV/AIDS treatment TOPAMAX (topiramate), an anti-epileptic and migraine prevention treatment TYLENOL, acetaminophen products. ULTRACET (tramadol HCI), an acute pain medication ULTRAM, treatment for moderate to moderately acute pain ULTRAPRO, partially absorbable mesh for repairing abdominal fascia VELCADE (bortezomib), an oncology treatment (non-J&J trademark) VIACTIV, soft calcium and multi-vitamin chews VICRYL (polyglactin 910), anti-bacterial coated suture VIPER, fixation system YONDELIS, marine derived anti-cancer agent ZARNESTRA, anti-cancer agent .
Load more

Recommended publications
  • 2019 Health for Humanity Report
    2019 Health for Humanity Report Progress in Sustainability Report Summary Contents Message from Our Chairman and CEO 3 Sustainability Approach 4 2019 Year in Brief 5 Better Health for All: Tackling the World’s 6 Toughest Health Challenges Better Health for All: Access, Community 7 Health & Innovation Responsible Business Practices 8 Environmental Health 9 UNICEF, the Government of Vietnam and Johnson & Johnson are partnering on a national program to train more than 500 ethnic minority midwives in remote regions to provide effective maternal and child health interventions including early essential newborn care in village clinics and homes. Photo by Paul Bettings Front cover Volunteers, frontline health workers and government officials at the launch of the Umurinzi vaccination program in Rwanda. In October 2019, Johnson & Johnson committed to donating up to 700,000 regimens of Janssen’s investigational Ebola vaccine to support the Ebola outbreak response in Rwanda and the Democratic Republic of the Congo. Photos by Rwanda Ministry of Health 2019 Health2017 for Health Humanity for HumanityReport Summary Report 33 Message from Our Chairman and CEO Dear Johnson & Johnson Stakeholders, We know this mission will always be unfinished, and affirmed unequivocally that there is a fundamental that we will occasionally fall short. But that only serves connection between serving all stakeholders and 2019 was a year of profound change and great contrasts as motivation to move faster than we’ve ever moved generating sustainable, long-term value. around the globe. before in making bigger strides toward some of our most ambitious goals. And as we’ve detailed in this Report, we The demands for global healthcare and responsible We saw unprecedented innovation and encouraging have plenty of positive momentum worth recognizing.
    [Show full text]
  • Maine State Maximum Allowable Cost List As of 02/10/2017
    Maine State Maximum Allowable Cost List as of 02/10/2017 CURRENT EFFECTIVE DATE DRUG FORM NDC MAC PRICE DATE UPDATED 1ST CHOICE LANCETS SUPER (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517065722 1ST CHOICE LANCETS THIN (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517015722 1ST CHOICE LANCETS ULTRA (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517030722 1ST CHOICE LANCETS ULTRA (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517035722 1ST TIER UNILET COMFORTOU (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517025736 1ST TIER UNILET COMFORTOU (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517065736 4-N-1 (Dimethicone Cream 1%) CREA 0.06060 04/28/2005 02/19/2013 61924020804 4-N-1 (Dimethicone Cream 1%) CREA 0.06060 04/28/2005 02/19/2013 61924020816 A & D ZINC OXIDE (Dimethicone-Zinc Oxide-Vitamin A-Vitamin D Cream 1- CREA 0.02730 04/28/2005 02/19/2013 00085141001 10%***) A & D ZINC OXIDE (Dimethicone-Zinc Oxide-Vitamin A-Vitamin D Cream 1- CREA 0.02730 04/28/2005 02/19/2013 00085141002 10%***) A + D PERSONAL CARE LOTIO (Emollient - Lotion**) LOTN 0.01940 03/13/2008 02/19/2013 00085113002 A+D FIRST AID (Skin Protectants Misc - Ointment***) OINT 0.03040 04/28/2005 02/19/2013 41100080545 A-SOY (Nutritional Supplement Liquid**) LIQD 0.01410 04/28/2005 02/19/2013 83744055027 Abacavir Sulfate Tab 300 MG (Base Equiv) TABS 4.20626 04/08/2016 04/05/2016 ABSORBASE (Skin Protectants Misc - Ointment***) OINT 0.03040 04/28/2005 02/19/2013 46287050704 ABSORBASE (Skin Protectants Misc - Ointment***) OINT 0.03040 04/28/2005 02/19/2013
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • “The Silver Sheet” MEDICAL DEVICE QUALITY CONTROL
    F-D-C REPORTS — FOUNDED 1939 $665 A YEAR ® www.TheSilverSheet.com“The Silver Sheet” MEDICAL DEVICE QUALITY CONTROL Vol. 13, No. 2 February 2009 THE NEWS THIS ISSUE • RECALLS SOARED TO THEIR HIGHEST POINT EVER IN 2008, with companies recalling a total of 845 devices. Many of the recalls were related to software problems and tainted heparin. “The goal is to try and decrease those recalls,” says Tim Ulatowski, director of CDRH’s Office of Compliance. “So we’re trying to push that number down through effective enforcement actions and industry training.” There is good news, however: The number of Class I recalls fell from 23 in 2007 to only 17 in 2008 – industry’s best Class I showing since 2003. Also, the recall manager for a Virginia hospital chain tells what companies should do to make their recall letters clearer and easier to comply with. “We get some recall letters and we truly don’t know what to do with them,” Bea Haupt says................................................Below • COMPLETE TABLE OF RECALLS FROM 2008 includes 17 Class I (2%), 726 Class II (86%) and 107 Class III (12%) medical device events ............................................................................................................12 • WARNING LETTERS: I-Flow cited for QS and MDR reg violations in relation to its infusion pumps.........66 • IN BRIEF: New GHTF guidance instructs firms on the control of products and services obtained from suppliers; former OSEL Director Larry Kessler is concerned that CDRH doesn’t always follow scientific principles and practices .......................................................................................................Back page Problems Related To Software, Heparin Help Push Recalls To All-Time High Also, FDA And Industry Experts Give Tips For Composing Recall Letters The number of recalled medical devices counting methods are typically negligible; the skyrocketed last year to its highest point ever, agency counted 831 total recalls in FY 2008 and spurred on by a large volume of Class II recalls 664 in FY 2007.
    [Show full text]
  • SWHPCGV (A6) Scott & White Health Plan Group Value Closed
    SWHP Group Value Formulary Federal Employees Health Benefits Program 3rd Quarter 2021 P a g e | 2 Table of Contents What is my prescription drug coverage? ...................................................................... 3 What is the Scott & White Health Plan Group Value Formulary? .................................. 3 How was the formulary created and how are new medications reviewed? .................. 3 Does the formulary ever change? ................................................................................ 3 How am I notified of changes to the formulary? .......................................................... 4 What are brand-name and generic drugs? ................................................................... 4 What is generic substitution? ...................................................................................... 4 What are specialty drugs? ........................................................................................... 4 What are pharmaceutical management procedures?................................................... 5 Are there any restrictions on my coverage? ................................................................. 5 How do I request an exception to the SWHP formulary?.............................................. 5 What drugs are not covered by my prescription drug benefit? ..................................... 5 How much medication does my copayment cover and does my plan cover maintenance medications? ........................................................................................
    [Show full text]
  • 2021 Bright Formulary (List of Covered Drugs)
    2021 Bright Formulary (List of Covered Drugs) Bright Health Individual and Family Plans Colorado PLEASE READ: This document contains information about the drugs Bright Health covers in their Individual and Family plans. This formulary was updated on 09/01/2021. For more recent information or other questions, please contact us at 833-661-1988 or visit www.brighthealthplan.com. PA - Prior Authorization QL - Quantity Limits ST - Step Therapy OTC - Over the i counter Welcome to Bright Enclosed you will find a list of the drugs included in our Bright Health Individual and Family plans from January 1, 2021 - December 31, 2021. As you review, be sure to have your medications on hand so you can confirm your prescriptions are covered and compare dosage and pricing of the drugs you take. Keep in mind, this document includes a comprehensive list of drugs (formulary) included in our Individual and Family plans. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. As a Bright Health member, you must generally use in-network pharmacies to fill your prescriptions. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the 2021 calendar year. Sincerely, Your Bright Health team PA - Prior Authorization QL - Quantity Limits ST - Step Therapy OTC - Over the ii counter Frequently Asked Questions: What is a Formulary (drug list)? A formulary is a list of covered drugs selected by Bright Health in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]
  • Wellcare of South Carolina Medicaid Preferred Drug List
    2021 South Carolina Medicaid Comprehensive Preferred Drug List (List of Covered Drugs) Lista integral de medicamentos preferidos de South Carolina Medicaid (Lista de medicamentos cubiertos) WellCare of South Carolina 00 Please read: This document contains information about the drugs we cover in this plan. Please note: The South Carolina Medicaid Preferred Drug List is updated quarterly. Providers, please visit our website at https://www.wellcare.com/South- Carolina/Providers/Medicaid/Pharmacy to view updates to the preferred drug list. Members, please visit our website at https://www.wellcare.com/South-Carolina/Members/Medicaid-Plans/WellCare-of-South-Carolina/Pharmacy- Services to view updates to the preferred drug list. Importante: Este documento contiene información acerca de los medicamentos que tienen cobertura con este plan. Tenga en cuenta lo siguiente: La lista de medicamentos preferidos de South Carolina Medicaid se actualiza cada trimestre. Proveedores: visite nuestro sitio web en https://www.wellcare.com/South- Carolina/Providers/Medicaid/Pharmacy para ver las actualizaciones de la lista de medicamentos preferidos. Miembros: visite nuestro sitio web en https://www.wellcare.com/South-Carolina/Members/Medicaid-Plans/WellCare-of-South-Carolina/Pharmacy- Services para ver las actualizaciones de la lista de medicamentos preferidos. Last updated (4/1/2021) Última actualización (4/1/2021) CAD_67295M State Approved 01282021 ©WellCare 2021 SC1SMDCVR68980M_2021 Drug Name Preference Details Coverage Details *Adhd/Anti-Narcolepsy/Anti-
    [Show full text]
  • Frequently Asked Questions
    Frequently Asked Questions Why are these companies included on the "Do Test" list? The following companies manufacture products that are tested on animals at some stage of development. Those marked with a Ƈ are currently observing a moratorium on (i.e., current suspension of) animal testing. Please encourage them to announce a permanent ban. Listed in parentheses are examples of products manufactured by either the company listed or, if applicable, its parent company. For a complete listing of products manufactured by a company on this list, please visit the company's website or contact the company directly for more information. Companies on this list may manufacture individual lines of products that have not been tested on animals. They have not, however, eliminated tests on animals for their entire line of cosmetics and household products. What if a company isn't on either of PETA's lists? Some companies have refused to respond to specific questions about their testing practices. It appears likely that these companies do test on animals at some stage of product development, and their refusal to clarify their testing policies appears to be an attempt to mislead consumers. Other companies may be new. If you find a company not included on our lists, please share the company's contact information with PETA so that we can contact the company directly. Legend Ƈ The company is currently observing a moratorium on animal testing. 3M 3M Corporate 1-888-364-3577 www.solutions.3m.com Headquarters 3M Center St. Paul, Minnesota 55144-1000 Acuvue (Johnson & Johnson) Customer (800) 843-2020 www.acuvue.com/ Relations, D-QA 7500 Centurion Parkway Jacksonville, Florida 32256 Aim (Church & Dwight) P.O.
    [Show full text]
  • Mainecare MAC List Effective 12.11.2017
    Maine State Maximum Allowable Cost List as of 12/11/2017 CURRENT EFFECTIVE DATE DRUG FORM NDC MAC PRICE DATE UPDATED 1ST CHOICE LANCETS SUPER (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517065722 1ST CHOICE LANCETS THIN (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517015722 1ST CHOICE LANCETS ULTRA (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517030722 1ST CHOICE LANCETS ULTRA (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517035722 1ST TIER UNILET COMFORTOU (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517025736 1ST TIER UNILET COMFORTOU (Lancets***) MISC 0.08772 06/17/2011 02/19/2013 08517065736 4-N-1 (Dimethicone Cream 1%) CREA 0.06060 04/28/2005 02/19/2013 61924020804 4-N-1 (Dimethicone Cream 1%) CREA 0.06060 04/28/2005 02/19/2013 61924020816 A & D ZINC OXIDE (Dimethicone-Zinc Oxide-Vitamin A-Vitamin D Cream 1- CREA 0.02730 04/28/2005 02/19/2013 00085141001 10%***) A & D ZINC OXIDE (Dimethicone-Zinc Oxide-Vitamin A-Vitamin D Cream 1- CREA 0.02730 04/28/2005 02/19/2013 00085141002 10%***) A + D PERSONAL CARE LOTIO (Emollient - Lotion**) LOTN 0.01940 03/13/2008 02/19/2013 00085113002 A+D FIRST AID (Skin Protectants Misc - Ointment***) OINT 0.03040 04/28/2005 02/19/2013 41100080545 A-SOY (Nutritional Supplement Liquid**) LIQD 0.01410 04/28/2005 02/19/2013 83744055027 Abacavir Sulfate Tab 300 MG (Base Equiv) TABS 1.71062 09/15/2017 09/12/2017 Abacavir Sulfate-Lamivudine Tab 600-300 MG TABS 5.09004 10/13/2017 10/11/2017 Abacavir Sulfate-Lamivudine-Zidovudine Tab 300-150-300 MG TABS 19.77500 03/10/2017 03/08/2017
    [Show full text]
  • Creative Director 561.714.1585 Andy Mathurin
    Hello, I am: Looking for role as: Let’s Connect: Andy Mathurin Creative Director 561.714.1585 Associate Creative Director, [email protected] Brand Strategist New York What I do: PROFILE Brand Strategy Over 8 years leading branding and marketing concepts with career spanning 360 campaigns, broadcast, print, OOH, social, digital, video and experiential Identity Design across major worldwide brands. Energetic and a creative visionary offering Storytelling demonstrated expertise in all aspects of branding and strategy, with core focus Thought Leader on delivering business results. Team Builder Marketing WINS Project Management Successes have included winning several accounts for new business, resulting in agency being awarded Global Agency of the Year by AdAge & Adweek. Toolkit: AOR: Havas - Vascepa 2019, Havas - Alcon 2019, J3 - OGX 2018, UM - H&M 2017, UM - Sony 2017, BMW 2016, UM - Coca Cola 2016 Sketch XD Microsoft Office PROFESSIONAL EXPERIENCE Avocode 03.18 HAVAS | Manhattan, NY Photoshop Present Associate Creative Director Strategic partner, focusing on brand equity for healthcare and InDesign pharmaceutical brands. Responsible for new business and leading creative Illustration team/studio across all digital platforms (specializing in social). After Effects Brands include: Zicam, Alcon, GSK, NUCALA, TRELEGY, & ANORO. 09.14 Universal McCann Worldwide | Manhattan, NY 03.18 Personality: Associate Creative Director + Senior Art Director Hands-on leader in identity design. Champion participant in winning new Human business pitches. Guiding and advising clients on high-level executions. Confident Brands include: Sony Pictures, GoPro, McCormick, BMW... and more. Effective Communicator - Demonstrate strong leadership overseeing staff in the day-to-day projects Motivational Honest with Integrity - Deliver against demanding brand objectives and develop creative that Empathetic exceeds business needs, managing projects from concept through completion: timelines, budgets, schedules, etc.
    [Show full text]
  • Ethics and Social Responsibility
    Fundamentals of Business, Second Edition Chapter 4 Ethics and Social Responsibility Content for this chapter was adapted from the Saylor Foundation’s http://www.saylor.org/site/textbooks/Exploring%20Business.docx by Virginia Tech under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License. The Saylor Foundation previously adapted this work under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License without attribution as requested by the work’s original creator or licensee. If you redistribute any part of this work, you must retain on every digital or print page view the following attribution: Download this book for free at: http://hdl.handle.net/10919/84848 Lead: Stephen J. Skripak Contributors: Anastasia Cortes, Gary Walton, Anita Walz Digital and Print Production: Corinne Guimont with Robert Browder Alternative Text and Accessibility: Stephanie Edwards, Christa Miller, and Corinne Guimont Selected graphics: Brian Craig Cover design: Trevor Finney Student Reviewers: Jonathan De Pena, Nina Lindsay, Sachi Soni Project Manager/Editor: Anita Walz This chapter is licensed with a Creative Commons Attribution-Noncommercial-Sharealike 3.0 License. Download this book for free at: http://hdl.handle.net/10919/84848 VT Publishing, a division of the University Libraries at Virginia Tech August 2018 4. Chapter 4 Ethics and Social Responsibility Learning Objectives 1. Define business ethics and explain what it means to act ethically in business. 2. Explain why we study business ethics. 3. Identify ethical issues that you might face in business, such as insider trading, conflicts of interest, and bribery, and explain rationalizations for unethical behavior. 4. Identify steps you can take to maintain your honesty and integrity in a business environment.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]